Patch, not needle: Anodyne raises $12.6m for GLP-1 obesity patch

Boston biotech secures Series A funding to move its once-weekly GLP-1 obesity patch into first-in-human clinical trials. Is the weekly injection finally under threat? GLP-1 medicines have reshaped obesity treatment faster than almost any therapy in recent memory, turning household names like Ozempic and Wegovy into cultural phenomena. Yet for all their success, they still […] The post Patch, not needle: Anodyne raises $12.6m for GLP-1 obesity patch appeared first on Longevity.Technology .

This story was reported by Longevity.Technology. EUROPES curates Europe's most relevant coverage — read the full report at the original source.